Eli Lilly and Company and Lycia Therapeutics have signed a multi-year collaboration and licensing agreement for the discovery and development of novel lysosomal targeting chimera (LYTAC) degraders.
Shape Therapeutics has entered into a multi-target strategic collaboration and licence agreement with Roche to develop gene therapy for particular targets in the areas of Alzheimer’s disease, Parkinson’s disease, and rare diseases.
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Rydapt (midostaurin) as the first treatment for rare blood disorder.
CM Life Sciences II and SomaLogic have collaborated with Twist Bioscience to discover novel therapeutic targets and antibodies.
Aurinia Pharmaceuticals has bought two new pipeline assets to boost its rare autoimmune and kidney-related disease portfolio.
Gritstone bio and the Coalition for Epidemic Preparedness Innovations (CEPI) have signed a funding agreement to advance the development of the former’s second-generation Covid-19 vaccine programme (CORAL) against SARS-CoV-2 variants.
Biotherapeutics company GentiBio has raised $157m through a Series A funding round, which was led by Matrix Capital Management.
German pharmaceutical firm Bayer has agreed to acquire Vividion Therapeutic to strengthen its drug discovery capabilities.
Sanofi has agreed to acquire a mRNA therapeutics firm Translate Bio to advance the use of messenger RNA (mRNA) technology across vaccines and therapeutics development.
Biopharmaceutical company Ipsen and Exicure have collaborated to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational therapies to treat Angelman syndrome and Huntington’s disease.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.